EBOLA VACCINE INCHES TOWARD HUMAN CLINICAL TRIALS
166955
post-template-default,single,single-post,postid-166955,single-format-standard,bridge-core-1.0.5,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.1,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.0.2,vc_responsive
 

EBOLA VACCINE INCHES TOWARD HUMAN CLINICAL TRIALS

EBOLA VACCINE INCHES TOWARD HUMAN CLINICAL TRIALS

A whole-virus vaccine to confront Ebola, the rare but often fatal hemorrhagic disease that periodically erupts in sub-Saharan Africa, may soon be one step closer to the clinic.

With the help of experts at Waisman Biomanufacturing, within the University of Wisconsin-Madison’s Waisman Center, UW-Madison School of Veterinary Medicine Professor Yoshihiro Kawaoka will lead a $3 million effort to produce as many as 1,000 doses of an experimental vaccine that has already been proven to work safely in monkeys.

“The goal is to produce a safe and effective vaccine against Ebola virus for people,” says Kawaoka, a world expert on Ebola and influenza. The vaccine is planned for use in a phase 1 clinical trial in Japan and is the only whole-virus Ebola vaccine candidate under development.

 

READ FULL STORY